Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites
Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites
复制标题
DOI：
10.1111/j.1872-034x.2011.00873.x
复制
发表时间：
2011-11-01
影响因子：
4.2
通讯作者：
Tang, Hong
中科院分区：
文献类型：
--
作者：
Deng, Lihui;Tang, Hong
核苷（酸）类似物（NAs）已成为治疗慢性B型肝炎病毒感染的主流药物。然而，对NAs的耐药性已经成为获得持续病毒抑制的主要障碍。在讨论NAs抗性时，已经提出了术语和命名的标准化定义。对NAs的耐药性是由病毒、宿主和抗病毒药物因素的组合产生的。详细了解导致NAs耐药的突变位点的机制和影响对于设计合理的治疗和管理现有耐药患者非常重要。
Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment of chronic hepatitis B virus infection. Drug resistance to NAs, however, has posed a major obstacle in obtaining sustained viral suppression. Standardized definitions of terms and nomenclature in discussing NAs resistance have been proposed. Drug resistance to NAs is produced by a combination of viral, host and antiviral drug factors. A detailed understanding of the mechanisms and effects of mutation sites that cause resistance to NAs is important for the design of rational treatment and management of patients with existing drug resistance.